Difference between revisions of "Atypical small acinar proliferation"

From Libre Pathology
Jump to navigation Jump to search
Line 1: Line 1:
{{ Infobox diagnosis
| Name      = {{PAGENAME}}
| Image      =
| Width      =
| Caption    =
| Synonyms  = suspicious for prostate carcinoma
| Micro      = morphology of prostate carcinoma but less than 6 glands (major criteria: abnormal architecture (increased gland density, usu. small circular glands, "infiltrative growth" pattern), basal cells lost, cytological abnormalities (nuclear enlargement, nucleoli); minor criteria: nuclear hyperchromasia, wispy blue mucin, pink amorphous secretions, intraluminal crystalloid, amphophilic cytoplasm, adjacent HGPIN, mitoses)
| Subtypes  =
| LMDDx      = [[prostate adenocarcinoma]], benign prostate
| Stains    =
| IHC        = AMACR +ve, CK34betaE12 -ve, p63 -ve, PSA +ve
| EM        =
| Molecular  =
| IF        =
| Gross      =
| Grossing  =
| Site      = [[prostate gland]]
| Assdx      =
| Syndromes  =
| Clinicalhx =
| Signs      =
| Symptoms  =
| Prevalence = ~3-5% of prostate biopsies
| Bloodwork  = +/-PSA elevated
| Rads      =
| Endoscopy  =
| Prognosis  = increased risk of prostate carcinoma
| Other      = [[waffle diagnosis]] - used only on biopsy
| ClinDDx    =
| Tx        = re-biopsy, close follow-up
}}
'''Atypical small acinar proliferation''', abbreviated ''ASAP'', is a small number of [[prostate gland|prostate glands]] that are abnormal and suspicious for [[prostate carcinoma|carcinoma]].
'''Atypical small acinar proliferation''', abbreviated ''ASAP'', is a small number of [[prostate gland|prostate glands]] that are abnormal and suspicious for [[prostate carcinoma|carcinoma]].


It is also known as '''suspicious for carcinoma'''.<ref>THvdK. 19 June 2010.</ref> ASAP is preferred as it does not contain the word ''carcinoma'' and, thus, cannot be misread as ''carcinoma'', i.e. positive for malignancy.
It is also known as '''suspicious for carcinoma'''.<ref name=THvdK>THvdK. 19 June 2010.</ref> ASAP is preferred as it does not contain the word ''carcinoma'' and, thus, cannot be misread as ''carcinoma'', i.e. positive for malignancy.


==General==
==General==
Line 7: Line 38:
**Analogous to ''[[ASCUS]]'' on a pap test.
**Analogous to ''[[ASCUS]]'' on a pap test.
*ASAP should be used sparingly.
*ASAP should be used sparingly.
**One benchmark is < 3-5% of biopsies.<ref>THvdK. 19 June 2010.</ref>
**One benchmark is < 3-5% of biopsies.<ref name=THvdK>THvdK. 19 June 2010.</ref>
*Never diagnosed on excision, i.e. prostatectomy specimen.
*Never diagnosed on excision, i.e. prostatectomy specimen.


===Association with adenocarcinoma===
===Association with adenocarcinoma===
*On subsequent [[biopsy]] - chance of finding [[adenocarcinoma]] is approximately 40%; this is higher than if there is [[high-grade prostatic intraepithelial neoplasia]] (HGPIN).<ref>{{cite journal |author=Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M |title=Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy |journal=Clinics |volume=63 |issue=3 |pages=339–42 |year=2008 |month=June |pmid=18568243 |doi= |url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000300009&lng=en&nrm=iso&tlng=en}}</ref>
*On a subsequent biopsy the chance of finding [[adenocarcinoma]] is approximately 40%; this is higher than if there is [[high-grade prostatic intraepithelial neoplasia]] (HGPIN).<ref name=pmid18568243>{{cite journal |author=Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M |title=Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy |journal=Clinics |volume=63 |issue=3 |pages=339–42 |year=2008 |month=June |pmid=18568243 |doi= |url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000300009&lng=en&nrm=iso&tlng=en}}</ref>


===Management===
===Management===
*ASAP is considered an indication for re-biopsy;<ref>{{cite journal |author=Bostwick DG, Meiers I |title=Atypical small acinar proliferation in the prostate: clinical significance in 2006 |journal=Arch. Pathol. Lab. Med. |volume=130 |issue=7 |pages=952–7 |year=2006 |month=July |pmid=16831049 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=130&page=952}}</ref> in one survey of [[urologist]]s<ref>{{cite journal |author=Rubin MA, Bismar TA, Curtis S, Montie JE |title=Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? |journal=Am. J. Surg. Pathol. |volume=28 |issue=7 |pages=946–52 |year=2004 |month=July |pmid=15223967 |doi= |url=}}</ref> 41/42 (~98%) of respondents considered it a sufficient reason to re-biopsy.
*ASAP is generally considered an indication for re-biopsy;<ref name=pmid16831049>{{cite journal |author=Bostwick DG, Meiers I |title=Atypical small acinar proliferation in the prostate: clinical significance in 2006 |journal=Arch. Pathol. Lab. Med. |volume=130 |issue=7 |pages=952–7 |year=2006 |month=July |pmid=16831049 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=130&page=952}}</ref> in one study<ref name=pmid15223967>{{cite journal |author=Rubin MA, Bismar TA, Curtis S, Montie JE |title=Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? |journal=Am. J. Surg. Pathol. |volume=28 |issue=7 |pages=946–52 |year=2004 |month=July |pmid=15223967 |doi= |url=}}</ref> 41/42 (~98%) of urologists considered it a sufficient reason to re-biopsy.


==Microscopic==
==Microscopic==
Line 33: Line 64:


==IHC==
==IHC==
*Generally ''not'' contributory.
Usually stains like cancer:
Usually stains like cancer:
*AMACR +ve.
*AMACR +ve.
*CK34betaE12 -ve.
*CK34betaE12 -ve.
*p63 -ve.
*p63 -ve.
Note:
*Generally ''not'' contributory.
==Sign out==
<pre>
K. PROSTATE, LEFT LATERAL INTERIOR, BIOPSY:
- ATYPICAL SMALL ACINAR PROLIFERATION.
</pre>


==See also==
==See also==

Revision as of 01:40, 18 March 2014

Atypical small acinar proliferation
Diagnosis in short

Synonyms suspicious for prostate carcinoma

LM morphology of prostate carcinoma but less than 6 glands (major criteria: abnormal architecture (increased gland density, usu. small circular glands, "infiltrative growth" pattern), basal cells lost, cytological abnormalities (nuclear enlargement, nucleoli); minor criteria: nuclear hyperchromasia, wispy blue mucin, pink amorphous secretions, intraluminal crystalloid, amphophilic cytoplasm, adjacent HGPIN, mitoses)
LM DDx prostate adenocarcinoma, benign prostate
IHC AMACR +ve, CK34betaE12 -ve, p63 -ve, PSA +ve
Site prostate gland

Prevalence ~3-5% of prostate biopsies
Blood work +/-PSA elevated
Prognosis increased risk of prostate carcinoma
Other waffle diagnosis - used only on biopsy
Treatment re-biopsy, close follow-up

Atypical small acinar proliferation, abbreviated ASAP, is a small number of prostate glands that are abnormal and suspicious for carcinoma.

It is also known as suspicious for carcinoma.[1] ASAP is preferred as it does not contain the word carcinoma and, thus, cannot be misread as carcinoma, i.e. positive for malignancy.

General

  • It is a waffle diagnosis, i.e. it is not considered an entity with a distinct pathobiology.[2]
    • Analogous to ASCUS on a pap test.
  • ASAP should be used sparingly.
    • One benchmark is < 3-5% of biopsies.[1]
  • Never diagnosed on excision, i.e. prostatectomy specimen.

Association with adenocarcinoma

Management

  • ASAP is generally considered an indication for re-biopsy;[4] in one study[5] 41/42 (~98%) of urologists considered it a sufficient reason to re-biopsy.

Microscopic

Features:

  • Atypical appearing acini.
  • Limited extent - key feature.
    • Less than six glands.†

Note:

  • Deeper cuts didn't yield anything - important.
  • † There is no agreed upon minimum number of glands; however, one paper suggests that agreement among experts is low with 5 or less glands.[6]

DDx:

IHC

Usually stains like cancer:

  • AMACR +ve.
  • CK34betaE12 -ve.
  • p63 -ve.

Note:

  • Generally not contributory.

Sign out

K. PROSTATE, LEFT LATERAL INTERIOR, BIOPSY:
- ATYPICAL SMALL ACINAR PROLIFERATION.

See also

References

  1. 1.0 1.1 THvdK. 19 June 2010.
  2. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D (January 2007). "Atypical small acinar proliferation: biopsy artefact or distinct pathological entity". BJU International 99 (4): 780-5. PMID 17378841. http://www3.interscience.wiley.com/journal/118508438/abstract.
  3. Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M (June 2008). "Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy". Clinics 63 (3): 339–42. PMID 18568243. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322008000300009&lng=en&nrm=iso&tlng=en.
  4. Bostwick DG, Meiers I (July 2006). "Atypical small acinar proliferation in the prostate: clinical significance in 2006". Arch. Pathol. Lab. Med. 130 (7): 952–7. PMID 16831049. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=130&page=952.
  5. Rubin MA, Bismar TA, Curtis S, Montie JE (July 2004). "Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?". Am. J. Surg. Pathol. 28 (7): 946–52. PMID 15223967.
  6. Van der Kwast, TH.; Evans, A.; Lockwood, G.; Tkachuk, D.; Bostwick, DG.; Epstein, JI.; Humphrey, PA.; Montironi, R. et al. (Feb 2010). "Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies.". Am J Surg Pathol 34 (2): 169-77. doi:10.1097/PAS.0b013e3181c7997b. PMID 20061936.